Necrobiotic xanthogranuloma (NXG) is a rare chronic condition, belonging to the group non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly monoclonal gammopathy, MGUS and multiple myeloma. The case reported here NXG was diagnosed after 1 years of evolution in patient with asymptomatic multiple myeloma. After treatment with bortezomib, lenalidomid and dexamethasone, there was evident abrupt decrease of monoclonal immunoglobulin to not measurable level (complete remission of multiple myeloma) and in the same time was evident disappearance of cutaneous and hepatic lesions of NXG on FDG-PET/CT. The etiopathogenetic association of monoclonal immunoglobulin with NXG is documented in this case report with disappearance of NXG in the time of disappearance of monoclonal immunoglobulin.

Download full-text PDF

Source

Publication Analysis

Top Keywords

monoclonal immunoglobulin
16
multiple myeloma
12
necrobiotic xanthogranuloma
8
disappearance monoclonal
8
bortezomib lenalidomid
8
monoclonal
5
nxg
5
[complete remission
4
remission necrobiotic
4
disappearance
4

Similar Publications

The rapid, sensitive, and accurate detection of paralytic shellfish toxins (PSTs), such as saxitoxin (STX), is critical for protecting human health due to the frequent occurrence of toxic red tides. In this work, to address the low affinity of traditional mouse monoclonal antibodies (m-mAbs), rabbit monoclonal antibodies (r-mAbs) against STX were produced by a single B-cell sorting culture and a cross-selection strategy. The r-mAbs showed 100-fold improvement in sensitivity (IC = 0.

View Article and Find Full Text PDF

Elucidating the interaction between membrane proteins and antibodies requires whole-cell imaging at high spatiotemporal resolution. Lattice light-sheet (LLS) microscopy offers fast volumetric imaging but suffers from limited spatial resolution. DNA-based point accumulation for imaging in nanoscale topography (DNA-PAINT) achieves molecular resolution but is restricted to two-dimensional imaging owing to long acquisition times.

View Article and Find Full Text PDF

A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells.

Proc Natl Acad Sci U S A

January 2025

Key Laboratory of Molecular Nanostructure and Nanotechnology, Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.

Emerging evidence indicates that intratumor bacteria exist as an active and specific tumor component in many tumor types beyond digestive and respiratory tumors. However, the biological impact and responsible molecules of such local bacteria-tumor direct interaction on cancer therapeutic response remain poorly understood. Trastuzumab is among the most commonly used drugs targeting the receptor tyrosine-protein kinase erbB-2 (ErbB2) in breast cancer, but its resistance is inevitable, severely limiting its clinical effectiveness.

View Article and Find Full Text PDF

Microsporidiosis in Patients with Autoimmune Diseases Undergoing Monoclonal Antibody Associated Therapy.

Mycopathologia

January 2025

Sorbonne Université, Inserm U1135, Centre d'Immunologie et de Maladies Infectieuses (Cimi-Paris), AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, 184 rue Faubourg Saint Antoine, 175012, Paris, France.

We present Enterocytozoon bieneusi infection in four patients with autoimmune diseases undergoing prolonged monoclonal antibody therapies. Two patients suffered from inflammatory bowel disease and received anti-TNF therapies, whereas two other patients suffered from systemic lupus erythematosus with renal involvement and received anti-CD20 or anti-BLyS protein therapies. Three out of four patients consulted for diarrhea with abdominal pain without intestinal inflammation or bleeding at the time of sampling.

View Article and Find Full Text PDF

Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!